For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Ultragenyx Takes Over Mepsevii Marketing Authorization in Japan
July 15, 2022
- Shingrix Shows Cost-Effectiveness in Japanese Older Adults: GSK Analysis
July 15, 2022
- Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
- Mochida to Discontinue Filgrastim Biosimilars Despite 50% Share
July 14, 2022
- Financially Weak Companies Will Go Under If Annual Price Cuts Continue: Sawai Chair
July 14, 2022
- BMS Japan on Track to Achieve Goals in Mid-Term Biz Plan: Chief
July 14, 2022
- Shionogi’s Four-Day Workweek Not So Popular Yet, but Side Job Plan Gaining Traction
July 13, 2022
- Healios to Provide iPSC Line to RxCell; License Talks with StemAxon Gets Underway
July 13, 2022
- Ex-Novartis Exec Jugo Tsumura Takes Reins at Ferring Japan
July 12, 2022
- Takeda Showcases Manufacturing Line for Cell Therapy Alofisel
July 11, 2022
- Organon Curbs Shipment of Fertility Med Ganirest in Japan
July 11, 2022
- As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
- Shipment Restrictions Continue for Vyndaqel, Vynmac: Pfizer Japan
July 8, 2022
- Japan Ethical Drug Sales Surge 6.2% in May: Crecon
July 8, 2022
- Lilly Japan, Mitsubishi Tanabe Link Up to Copromote Diabetes Med Tirzepatide
July 8, 2022
- Meiji Pharma/KM Biologics Eager to Acquire mRNA Vaccine, Mull Collabs with Upstarts and Academia
July 7, 2022
- KD-414 Presumed to Have Superior Efficacy over Vaxzevria: KM Bio President
July 7, 2022
- PeptiDream, Nihon Medi-Physics Wind Up Collab for Peptide-RI Conjugates
July 7, 2022
- France’s Pierre Fabre Gets Europe Rights to Urovant OAB Med Vibegron
July 7, 2022
- Kissei Kicks Off Japan PIII for Linzagolix in Uterine Fibroids
July 7, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…